BTIG lowered the firm’s price target on DexCom (DXCM) to $80 from $85 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target raised to $84 from $77 at Citi
- Dexcom Executive Chairman Kevin Sayer Returns From Leave
- Dexcom Adds Google Executive Rick Osterloh to Board
- DexCom management to meet virtually with BTIG
- Dexcom’s $750 Million 2025 Buyback Plan Faces Uncertain Execution and Limited Assurance of Shareholder Value